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Background: Sub-Saharan Africa faces an epidemic of diabetes. Diabetes causes significant morbidity including
visual loss from diabetic retinopathy, which is largely preventable. In this resource-poor setting, health systems are
poorly organized to deliver chronic care with multiple system involvement. The specific skills and resources needed
to manage diabetic retinopathy are scarce. The costs of inaction for individuals, communities and countries are
likely to be high.
Discussion: Screening for and treatment of diabetic retinopathy have been shown to be effective, and cost-effective,
in resource-rich settings. In sub-Saharan Africa, clinical services for diabetes need to be expanded with the
provision of effective, integrated care, including case-finding and management of diabetic retinopathy. This
should be underpinned by a high quality evidence base accounting for differences in diabetes types, resources,
patients and society in Africa. Research must address the epidemiology of diabetic retinopathy in Africa,
strategies for disease detection and management with laser treatment, and include health economic analyses.
Models of care tailored to the local geographic and social context are most likely to be cost effective, and
should draw on experience and expertise from other continents. Research into diabetic retinopathy in Africa can
drive the political agenda for service development and enable informed prioritization of available health
funding at a national level. Effective interventions need to be implemented in the near future to avert a large
burden of visual loss from diabetic retinopathy in the continent.
Summary: An increase in visual loss from diabetic retinopathy is inevitable as the diabetes epidemic emerges in
sub-Saharan Africa. This could be minimized by the provision of case-finding and laser treatment, but how to do
this most effectively in the regional context is not known. Research into the epidemiology, case-finding and
laser treatment of diabetic retinopathy in sub-Saharan Africa will highlight a poorly met need, as well as guide
the development of services for that need as it expands.
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Sub-Saharan Africa (SSA) faces an epidemic of non-
communicable disease (NCD) driven by urbanization,
lifestyle, poor diet, smoking, environmental factors and
aging. Increased life expectancy and population growth
(in part from successes in combating communicable
diseases) add to the NCD burden to society, health services
and the individual [1].* Correspondence: philipburgess@doctors.org.uk
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reproduction in any medium, provided the orThe International Diabetes Federation has estimated
that the number of adults with diabetes in Africa will
double in 20 years, from 12 million in 2010 to 24 million
in 2030 [2]. Diabetes causes significant morbidity, disability
and early mortality. The diabetes epidemic therefore poses
significant health and socioeconomic challenges for a con-
tinent simultaneously facing other health challenges includ-
ing infectious diseases (HIV, tuberculosis and malaria) and
high levels of maternal and perinatal disorders and trauma.
Diabetes causes visual impairment (VI) through early-
onset cataract and diabetic retinopathy (DR), a progressive
disease of the retinal microvasculature. Cataract and DR
are the second and sixth leading causes of global VI,
respectively [3]. Both are included in the list of nine targetl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Health Organization (WHO) and the International Agency
for the Prevention of Blindness. Diabetes damages retinal
capillaries through prolonged exposure to hyperglycemia.
This leads to loss of supporting pericyte cells and tight
junctions between endothelial cells. In turn, this causes
leakage from capillaries, resulting in retinal edema; capillary
closure; and ischemia. An ischemic retina produces vascu-
lar endothelial growth factor (VEGF), which stimulates new
vessel growth (proliferative diabetic retinopathy, PDR). An
edematous or ischemic retina loses function, and this will
reduce vision if the central retina or macular is involved.
New vessels are prone to bleeding (vitreous hemorrhage)
and the accompanying fibrosis leads to tractional retinal
detachment. Thus the sight-threatening manifestations of
DR are proliferative retinopathy and diabetic maculopathy,
which are both preventable and treatable before vision is
lost. The risk of development and progression of retinop-
athy has been shown in developed economies to be related
to glycemic control or HbA1c [4-7], blood pressure [4,8-11]
and blood lipid levels [12]. Laser photocoagulation has been
shown to be effective at reducing visual loss in patients
with PDR [13] and macular edema [14] if timely treatment
is performed.
The epidemiology of DR in Africa has been systematically
reviewed by our group [15]. This review identified no
community-based cross-sectional or cohort studies of DR
from SSA on which to base incidence or prevalence esti-
mates in the population with diabetes. A recent population-
based survey (n = 4,414) in Nakuru, Kenya, identified a
prevalence of ‘any DR’ of 35.9% (95% CI: 29.7, 42.6)
and of ‘severe non proliferative DR or PDR’ of 13.9%
(95% CI: 10.0, 18.8) in 277 people with diabetes [Bastawrous,
personal communication]. Clinic-based studies report
a wide range of prevalence, often with higher levels of
sight-threatening disease, but these are subject to bias.
The proportion of any VI in African populations due
to DR is largely unknown. A recent population-based
study from Cape Town, South Africa, of visual loss
using WHO methods identified DR as the cause of 8% of
blindness and 11% of severe visual loss in persons ≥50 years
[16]. Population-based surveys of VI usually underestimate
DR as a cause. Retinal causes of VI are often recorded
together as one category, and are not recorded if there is
no fundal view (for example, due to cataract). Rectifiable
causes of VI (for example, cataract) are recorded in prefer-
ence to preventable or untreatable causes [17].
In this article we first review the evidence on detection
and management of DR in Africa. We discuss the potential
costs and benefits of action on DR within an integrated
strategy for diabetes care. Finally we propose that, drawing
on experience and expertise from other continents, re-
search into DR in Africa can drive the political agenda
for service development.Discussion
Evidence on natural history and management of diabetic
retinopathy in an African setting is lacking
Determinants of severity and progression
The prevalence and incidence of sight-threatening DR in
developed countries have been well documented [18-20].
Associations between systemic factors and the development
of sight-threatening DR in these populations are well
known [4-12]. By contrast, only two cohort studies have
investigated determinants of severity and progression of DR
in Africa: a population based study from Mauritius [21] and
a relatively small study of patients with type 1 diabetes in
South Africa [22]. There may be additional factors which
affect DR in SSA, and poor glycemic and blood pressure
control may result in rapid progression.
As well as the type 1 and 2 paradigm, additional forms
of diabetes are described on the continent including
‘malnutrition-related diabetes’ and ‘atypical ketosis prone
diabetes’ [1]. In many African countries, the diet is high
in refined carbohydrates (for example, maize meal),
something that is difficult to change because of cultural
and economic reasons. Population-specific risk factors are
also likely to affect the spectrum of pathology encountered.
Diabetes increases the incident risk of tuberculosis, with
worsened outcomes for both [23,24]. Antiretroviral therapy,
and possibly HIV itself, is associated with an increased
risk of developing metabolic syndrome and diabetes [24].
However, the effect of these factors, as well as of others
including infective diseases and deficient micronutrients,
on DR are unknown.
Effectiveness of screening and laser treatment
Laser treatment for PDR involves ablation of the periph-
eral retina with 1,000 to 5,000 spaced burns to reduce the
amount of ischemic retina and the VEGF it produces.
Laser for diabetic macular edema involves applying the
treatment directly to leaking microaneurysms, and gentle
laser (up to 300 burns) to the macula, thought to stimulate
cellular fluid pumps. Laser treatment cannot be used on
vision loss caused by ischemic maculopathy. Effectiveness
of laser photocoagulation for DR in the African population
is assumed from landmark studies of peripheral retinal
laser and macular laser in Europe and North America
[13,14]. There is no evidence that the benefits of timely
laser treatment will be any less in an African population
than they are in developed countries.
There have been scattered reports of successful attempts
to screen patients attending diabetes clinics for DR [25-29].
Screening using retinal photography has been piloted
[26,27,29]. However, most reports have come from South
Africa and these efforts have largely been initiated by local
hospitals or by external funding and support. Mumba et al.
[29] in Tanzania attempted to develop a register of known
patients with diabetes. Defining an eligible population is an
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challenge in resource-poor settings. Apart from rudimen-
tary costing [26], no evidence on cost effectiveness of
screening programs on the continent is available. The fact
that patients present late with diabetes must be considered.
Late presentation with established complications, in part
due to poor education and large indirect costs of accessing
care, may affect the benefits of screening. Targeted case
findings may be more appropriate.
Costs of action and inaction
Diabetes and its complications affect the working age
population
The costs of diabetes to Africa are significant, and are
rising rapidly. Kirigia et al. [30] estimated that the total
economic cost (direct and indirect) of diabetes in the
WHO Africa region in 2000 was US$67 billion: equivalent
to US$8,836 per person with diabetes per year. A significant
proportion of this figure is accounted for by the oppor-
tunity cost of productive time lost due to permanent
disability and premature mortality. The cost of compli-
cations was excluded from this study and therefore
true costs are underestimated.
The burden of diabetes and its complications is borne
predominantly by the working age population [31]. DR
is the commonest cause of blindness in the working
population in the USA and Europe [32]. A disease which
reduces the economic activity of this group affects individ-
ual, household and national economies. To our knowledge,
no study has addressed the specific costs of DR in Africa.
This information is critical for policymakers to highlight
the importance of introducing cost-effective interventions
for primary prevention and subsequently detection and
treatment of DR.
There is a scarcity of resources for treating DR
The agenda for diabetes care in SSA is dominated at a
national level by poorly resourced health services and at
a community level by poverty. The International Diabetes
Federation has estimated that in 2010 national funding for
the care of diabetes in Africa was just US$111 per person
[33]. This figure is equivalent, on average, to 7% of na-
tional healthcare expenditure but varies widely between
countries. In Malawi the total annual per capita expend-
iture on all healthcare was only US$25 [34]. Opportunity
costs will also be lower with the Gross National Income
per capita only being $330, but it is clear that current ex-
penditure is a fraction of the cost of the disease. Limited
public funding means individual patients and their fam-
ilies may have to spend significant proportions of their in-
come on diabetes treatment. Diabetes care must compete
with infective diseases and other healthcare initiatives in
terms of political and financial priorities. It does not lend
itself to the vertical programs favored by donors. However,political attention is now turning to NCDs, as witnessed by
the United Nations high-level meeting on NCD prevention
and control, held in September 2011 [35]. Policy makers
require evidence-based guidance on resource allocation.
The rise of NCDs in Africa demands not only re-
source allocation but massive reorganization of health
systems. SSA faces a large burden of infectious diseases
(HIV, tuberculosis and malaria) and high levels of maternal
and perinatal disorders and trauma. Services have trad-
itionally been organized to manage distinct health events
(for example, episodes of infection, child birth). NCDs
demand effective, integrated multidisciplinary services over
a lifetime. This is a significant challenge for health providers
as it impacts on all elements of health systems: workforce,
facilities, technology and pharmaceuticals as well as lead-
ership and governance. Reductions in microvascular com-
plications from improved glycemic and blood pressure
control, as shown in the Diabetes Complications and
Control Trial [5] and United Kingdom Prospective Diabetes
Study [8], will be maximized if monitoring and medications
are consistently available. Similarly, provision of services for
detection and management of complications, including DR,
must be consistent rather than intermittent.
In many SSA countries, services for detection and
management of DR are currently rudimentary and only
available in urban settings. There is a significant shortfall of
ophthalmologists. A recent survey showed that, while the
number of practitioners is increasing in developing coun-
tries, the population aged ≥60 years is growing at a greater
rate [36,37]. This suggests that the gap between need and
supply is widening. Referral pathways between primary and
secondary care, and those between diabetic clinics and oph-
thalmic services, are poorly organized. Patients do not have
a family practitioner to help them negotiate services for
diabetic complications. Indirect costs of attending hospital
are high, and may be perceived as unnecessary when eye
disease is not apparent, prior to visual loss.
In Malawi, a country of 15.2 million people [38], there
are only seven practicing consultant ophthalmologists.
The majority of ophthalmic patients are seen by ophthalmic
clinical officers (OCOs) who receive relatively little training
in retinal examination and diagnosis. Ophthalmologists and
OCOs are overwhelmed by cataract, ocular trauma, infec-
tious disease and pediatric ophthalmology so can devote
limited time to retinal disease management. In many SSA
countries, lack of equipment is limiting: in Malawi there is
no retinal imaging to support diagnoses; there are now two
lasers provided by external support. These factors result in
the under-development of skills in DR management.
Barriers to effective care delivery
Diabetes can be thought of as an index case for NCD
healthcare delivery in Africa and developing countries
worldwide. It is a chronic disease requiring complex
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of body systems; detection and management requires a
number of specialist medical services. The education
and empowerment of patients is an important part of
disease management. In addition to economic factors, a
number of barriers exist to delivery of care for diabetes
and its complications. WHO has identified the following
problems for healthcare delivery in developing countries:
lack of organizational structure for chronic disease care;
minimal staffing and training provided to healthcare
workers; minimal communication with the public to
address preventative strategies; non-existence of organized
healthcare information systems; and lack of involvement
and integration with other community resources [39]. In
Africa, these barriers translate into the inadequacies in
diabetes care identified by Whiting et al. (listed below)
[40]. We have identified a number of specific barriers to
DR care in Africa which are listed below.
Inadequacies in diabetes care as identified by Whiting
et al. [40]
1 Poor patient attendance at clinics
2 Low doctor to patient ratio leading to short
consultation times and little or no time for patient
education
3 Low staff levels including a lack of trained nurses
and other health workers
4 Lack of staff training specific to diabetes
5 A lack of systematic evaluation and monitoring of
the complications of diabetes
6 Non-existent or inadequate referral systems
7 Poor record keeping
8 Non-existent diabetes multidisciplinary healthcare
teams
9 Lack of infrastructure to support services
10 Lack of national policies
Specific barriers to diabetic retinopathy care in the
African region
1 Lack of ophthalmologists
2 Low number of ophthalmologists with training and
experience in management of DR
3 Low numbers of opticians and OCOs to perform
opportunistic screening; commercial opticians are
only accessible to the wealthy
4 Lack of training for opticians and OCOs in fundoscopy
5 Inadequate referral systems from primary to
secondary care and from medical departments to
ophthalmic services
6 Non-existent systematic screening programs
7 Little access to imaging technology including
fluorescein angiography and optical coherence
tomography8 Lack of treatment infrastructure including lasers and
laser maintenance
9 Lack of national policies and low government
priority
Lessons for sub-Saharan Africa can be learnt from other
settings
Integration of diabetes services
The evolving African diabetes epidemic necessitates a
coordinated response that involves integrating services
at a number of levels. At a community level, interventions
for the control and management of NCDs are necessary.
Several models exist in South Africa, for example the
Community Health Intervention Programme and the
Woolworths Health Promotion Programme [41]. The ef-
fect of these programs on NCD remains under evaluation
[41]. Expansion of health center- and also hospital-based
diabetes clinics is required on a massive scale. Primary
prevention of complications by systemic risk factor
management is a priority. Services must be tailored to
a resource-poor environment and the local geographic
and socioeconomic context. With such a rapid increase
in patient numbers, a simplification of some services
has been proposed. This might resemble the streamlin-
ing of HIV and AIDS services that was necessary to
achieve antiretroviral therapy roll out in many states in
SSA [42]. Some have advocated a ‘poly pill’ approach to
vascular risk factor management in Africa, although
this approach has significant drawbacks [43].
Systematic evaluation of complications with robust
referral mechanisms to specialist services is required. The
coordination of services at a local level aids this process.
Provision of medical management of diabetes, patient
education, and detection of complications via, for ex-
ample, screening for DR at a single time and place in the
community improve access to care. In resource-poor
settings patients may travel long distances to attend health
services incurring transport costs and loss of income. The
involvement of government agencies is key to long-term
service development. Outside funding and expertise may
be vital in setting up health systems. However, sustainabil-
ity and large-scale roll out of services necessitates national
policies. Patient organizations are important advocates for
services and can help create political momentum.
Laser photocoagulation is the mainstay of treatment for
diabetic retinopathy and maculopathy
The effectiveness of laser photocoagulation at reducing
the likelihood of VI and blindness in patients with PDR
[13] and macular edema [14] is well established. Recent evi-
dence demonstrates better outcomes in the short-term
from intra-vitreal anti-VEGF agents (injected intra-ocularly)
in diabetic maculopathy that has already reduced vision
[44]. This topic is the subject of a recent Cochrane review
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tions, will be increasingly used in resource-rich economies
although with a continued role for laser. At present
these agents are prohibitively expensive for widespread
use in resource-poor countries (approximately US$800
per injection for the drug alone). However, off-label
use of the systemic anti-VEGF, bevacizumab (Avastin)
(approximately US$70 per injection), is used in some
African tertiary centers on a paying patient basis, an
approach supported by the BOLT study [46]. Vitreoretinal
surgery has an important role in managing advanced
disease. However, published data from this setting is
sparse and more research on long-term outcomes and
cost effectiveness is required.
Provision of laser services requires substantial initial
investment in equipment and training of ophthalmologists.
However, equipment upkeep costs are small and there are
no on-going drug costs. The inadequacy of retinal training
and paucity of referral networks are significant barriers to
service development for DR. A number of proposals to
confront these issues are listed below. Our clinical and
research group has demonstrated that provision of a
laser treatment service is feasible in SSA albeit with
external support. In Queen Elizabeth Central Hospital,
Blantyre, Malawi, set-up costs of equipment and train-
ing of ophthalmologists has been funded by an outside
agency: the World Diabetes Foundation. OCOs have
been trained in the recognition and referral of DR with
funding from the same agency.
Proposals to improve retinal training and retinal refer-
ral networks in sub-Saharan Africa
1 Increase the number of ophthalmologists trained
and working in the region to allow increased
sub-specialization
2 Provision of imaging and treatment infrastructure to
allow sub-specialty practice
3 Creation of regional centers of excellence in Africa
for provision of tertiary retinal care and training
4 Development of retinal research networks:
providing funding both for personnel and
equipment, facilitating income generation for eye
units, setting standards for clinical practice,
improving the evidence base for this setting,
setting the political agenda and attracting
excellent clinicians.
5 Prioritization of sub-specialty development in
post-graduate training programs
6 Promotion of partnership arrangements with retinal
centers in developed countries to facilitate
knowledge and skill sharing
7 Provision of retinal fellowships tailored to
developing world trainees in retinal centers in
developed countries8 Use of donor and government funds to minimize
costs of such fellowships for trainees on condition of
return to practice in country of origin
Effectiveness and cost effectiveness of systematic diabetic
retinopathy screening in western settings is well established
Various methods of screening for DR are available.
Slit-lamp examination by a trained ophthalmologist
and retinal photography with grading of retinopathy by
accredited graders can be considered the reference
standards for disease detection [47]. Examination with
the direct ophthalmoscope is less sensitive and specific
for DR [47]. The cost effectiveness of DR screening has
been excellently reviewed by Jones et al. [48]. System-
atic screening is cost-effective for sight years preserved
compared with no screening. Variation in age of onset
of diabetes, glycemic control, sensitivity of the screening
test and compliance rates influence the cost-effectiveness
of screening programs.
Digital photography with telemedicine links, as used
by the English National Screening Programme [49], has
the potential to deliver cost-effective, accessible screening
to rural and remote populations. Unfortunately, fundus
cameras remain prohibitively expensive. Development of
lower cost solutions could radically alter the landscape for
DR care in Africa; research into appropriate technologies
is needed in addition to studies of disease epidemiology
and clinical trials of detection and management strategies.
Optimum screening intervals have yet to be defined and
research on targeted screening based on disease risk fac-
tors is on-going.
In Europe, sound evidence has driven service development
DR is the most common cause of blindness in the working
age population in the USA and Europe [32]. Landmark
epidemiological studies have demonstrated prevalence,
incidence and progression of the disease in the UK
[50], Europe [51,52] and North America [53]. Studies
including Diabetes Complications and Control Trial
[5], United Kingdom Prospective Diabetes Study [8],
and the Action to Control Cardiovascular Risk in Diabetes
trial [54] have shown that control of systemic risk factors
can prevent the microvascular complications of diabetes
including retinopathy. Tight glycemic control also reduces
incidence of cataract [55]. The effectiveness and cost
effectiveness of systematic screening programs for DR
has been demonstrated [56]. This strong evidence base
has driven the political agenda for service development
for diabetes and its complications. Further high-quality
research on the epidemiology of DR in Africa, and on
the effectiveness and cost effectiveness of DR care
models tailored to local needs is necessary. This evi-
dence can effect change in national policies which will
transform services.
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The Indian subcontinent has the greatest number of indi-
viduals with diabetes globally [2]. India and surrounding
states face many of the same barriers to DR care recognized
in Africa: lack of resources and trained manpower to screen
and treat the large number of people with DR; unequal dis-
tribution of resources between urban and rural areas; and
populations with high levels of poverty and poor education
many of whom are remote from health services.
A variety of screening and treatment models have been
described in India, many utilizing advances in informa-
tion, medical and communication technology to reduce
inequalities in service delivery. Examples include the
Aravind Teleophthalmology Network and the Sankara
Netralaya Teleophthalmology Project [57]. Economic
modeling analysis has been performed on the latter:
the rural teleophthalmology program was cost effective
compared to no screening [58]. From a health provider
perspective, screening at up to 2-year intervals was cost
effective while from a societal perspective screening once
every 5 years was cost effective [58]. Sustainable models of
screening and treatment for DR in Africa could be modeled
on those already operational in India.
Summary
Improvement of services for people with diabetes and its
complications is an urgent priority for Africa. The cost
of inaction for individuals, communities and countries is
likely to be high. The first priorities for diabetes care deliv-
ery must be adequate disease detection and appropriate
medical management: primary prevention of complications.
However, detection and management of diabetes complica-
tions including DR within effective integrated diabetes
services in an African setting is feasible. Expansion of clin-
ical services requires a shift in national health priorities. A
much better evidence base is needed to effect this change.
Understanding the scale of the problem and areas where
intervention is required will enable informed prioritization
of available health funding at a national level.
There is a pressing need for high-quality research into
the epidemiology of DR in Africa. The research agenda
must also address strategies for disease detection and
management and include health economic analyses.
Models of care tailored to the local geographic and social
context are most likely to be cost effective. Drawing on
experience and expertise from other continents will aid
design of clinical trials and, in turn, service development.
We recognize the complex challenges inherent in health-
care provision in SSA. However, effective interventions
need to be implemented in the near future to avert a large
burden of visual loss from DR on the continent.
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